title: Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
abstract: Treatment with fluoxetine hydrochloride was compared with treatment with clomipramine hydrochloride in two groups of patients with obsessive-compulsive disorder using two different experimental designs. In the first group of 11 patients with obsessive-compulsive disorder studied using a randomized, double-blind, crossover design, treatment with fluoxetine for 10 weeks was found to produce therapeutic effects similar to treatment with clomipramine for 10 weeks. There were significantly fewer total side effects reported during fluoxetine than clomipramine treatment. Drug tapering and placebo substitution in the 4-week crossover interval phase led to substantial relapses in obsessive-compulsive disorder symptoms and depression. Furthermore, responses to the second drug took as long to occur as responses to the first drug, although both drugs are thought to act by a common mechanism, serotonin uptake inhibition. A second group of 21 patients with obsessive-compulsive disorder that had been previously stabilized on clomipramine treatment with at least partial benefit were crossed over to fluoxetine treatment in a double-blind fashion. After 10 weeks of fluoxetine administration, most patients manifested behavioral rating scores of obsessive-compulsive disorder and depressive symptoms that were comparable with precrossover ratings completed during clomipramine treatment. A significant exacerbation in obsessive-compulsive disorder and depression ratings as well as a similar lag in therapeutic efficacy were also noted in this second cohort of patients with obsessive-compulsive disorder. Platelet 5-HT concentrations were reduced 95% during both clomipramine and fluoxetine treatment periods. These results suggest that fluoxetine may represent a viable alternative to clomipramine in the treatment of obsessive-compulsive disorder, although further studies with larger sample sizes are needed.
authors.affiliation: Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health Clinical Center, Bethesda, MD 20892.
authors.forename: T A
authors.initials: TA
authors.lastname: Pigott
authors.forename: M T
authors.initials: MT
authors.lastname: Pato
authors.forename: S E
authors.initials: SE
authors.lastname: Bernstein
authors.forename: G N
authors.initials: GN
authors.lastname: Grover
authors.forename: J L
authors.initials: JL
authors.lastname: Hill
authors.forename: T J
authors.initials: TJ
authors.lastname: Tolliver
authors.forename: D L
authors.initials: DL
authors.lastname: Murphy
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D012701:Serotonin / Q000378:metabolism
chemical_list: D005473:Fluoxetine; D012701:Serotonin; D002997:Clomipramine